钙结合蛋白S100A9已成为肿瘤学中的关键生物分子因子,与许多恶性肿瘤有关。这项全面的生物信息学研究超越了传统的界限,调查S100A9在不同肿瘤实体中的预后和治疗潜力。利用广泛的生物信息学工具和公开可用的癌症基因组学数据库,例如TCGA,我们系统地检测了S100A9基因。我们的方法包括差异表达分析,突变负担评估,蛋白质相互作用网络,和生存分析。这个强大的计算框架提供了S100A9在癌症生物学中的作用的高分辨率视图。这项研究精心探索了S100A9的致癌方面,综合分析其与预后的关系,肿瘤突变负荷(TMB),微卫星不稳定性(MSI),DNA甲基化,以及免疫细胞在各种肿瘤类型中的浸润。这项研究提供了一系列人类癌症中S100A9表达的全景,揭示了一个异质的表达景观。在BLCA(膀胱尿路上皮癌)等恶性肿瘤中检测到S100A9表达升高,CESC(宫颈鳞状细胞癌和宫颈腺癌),COAD(结肠腺癌),ESCA(食管癌),和GBM(多形性胶质母细胞瘤),虽然在BRCA(乳腺浸润性癌)中发现表达降低,HNSC(头颈部鳞状细胞癌),和KICH(肾生色)。这种不同的表达模式表明S100A9在癌症生物学中的作用是多方面的和依赖于环境的。预后方面,S100A9表达与不同癌症类型的患者预后可变相关。此外,在9种癌症类型中,其表达与TMB和MSI密切相关。详细检查六种选定的肿瘤-BRCA,CESC,KIRC(肾肾透明细胞癌),LUSC(肺鳞状细胞癌),SKCM(皮肤皮肤黑色素瘤);STAD(胃癌)-显示S100A9表达与大多数免疫细胞的浸润呈负相关,但与中性粒细胞呈正相关,M1巨噬细胞,和激活的NK细胞,强调S100A9和肿瘤免疫环境之间的复杂相互作用。这种生物信息学合成认为S100A9是癌症进展的重要参与者,提供有价值的预后见解。数据强调了S100A9作为预后生物标志物的实用性及其作为治疗靶标的潜力。治疗意义深远,提示S100A9活性的调节可显著影响癌症管理策略。
The calcium-binding protein
S100A9 has emerged as a pivotal biomolecular actor in oncology, implicated in numerous malignancies. This comprehensive bioinformatics study transcends traditional boundaries, investigating the prognostic and therapeutic potential of
S100A9 across diverse neoplastic entities. Leveraging a wide array of bioinformatics tools and publicly available cancer genomics databases, such as TCGA, we systematically examined the S100A9 gene. Our approach included differential expression analysis, mutational burden assessment, protein interaction networks, and survival analysis. This robust computational framework provided a high-resolution view of
S100A9\'s role in cancer biology. The study meticulously explored
S100A9\'s oncogenic facets, incorporating comprehensive analyses of its relationship with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration across various tumor types. This study presents a panoramic view of S100A9 expression across a spectrum of human cancers, revealing a heterogeneous expression landscape. Elevated
S100A9 expression was detected in malignancies such as BLCA (Bladder Urothelial Carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD (Colon adenocarcinoma), ESCA (Esophageal carcinoma), and GBM (Glioblastoma multiforme), while reduced expression was noted in BRCA (Breast invasive carcinoma), HNSC (Head and Neck squamous cell carcinoma), and KICH (Kidney Chromophobe). This disparate expression pattern suggests that S100A9\'s role in cancer biology is multifaceted and context-dependent. Prognostically, S100A9 expression correlates variably with patient outcomes across different cancer types. Furthermore, its expression is intricately associated with TMB and MSI in nine cancer types. Detailed examination of six selected tumors-BRCA, CESC, KIRC (Kidney renal clear cell carcinoma), LUSC (Lung squamous cell carcinoma), SKCM (Skin Cutaneous Melanoma); STAD (Stomach adenocarcinoma)-revealed a negative correlation of S100A9 expression with the infiltration of most immune cells, but a positive correlation with neutrophils, M1 macrophages, and activated NK cells, highlighting the complex interplay between S100A9 and the tumor immune environment. This bioinformatics synthesis posits S100A9 as a significant player in cancer progression, offering valuable prognostic insights. The data underscore the utility of S100A9 as a prognostic biomarker and its potential as a therapeutic target. The therapeutic implications are profound, suggesting that modulation of S100A9 activity could significantly impact cancer management strategies.